Company: AZN
Filing Date: 2025-10-20
Form Type: 6-K
Source: 0001654954-25-011951
Chunk: 6

Company: ASTRAZENECA PLC
Filing Date: 2025-10-20
Form: 6-K
Chunk 6
---
label/2023/761224s003lbl.pdf . Accessed October 2025.

10. TEZSPIRE (tezepelumab) Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/tezspire-epar-product-information_en.pdf . Accessed October 2025.

11. AstraZeneca news release. TEZSPIRE approved in Japan for the treatment of severe asthma. Available at: https://www.astrazeneca.com/media-centre/press-releases/2022/tezspire-approved-in-japan-for-severe-asthma.html . Accessed October 2025.

12. Corren J, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med . 2017;377:936-946.

13. Varricchi G, et al. Thymic Stromal Lymphopoietin Isoforms, Inflammatory Disorders, and Cancer. Front Immunol. 2018;9:1595.

14. Xolair (omalizumab) Summary of Product Characteristics; Available at: https://www.ema.europa.eu/en/documents/product-information/xolair-epar-product-information_en.pdf . Accessed October 2025.

15. Xolair (omalizumab) US prescribing information; Available at: https://www.gene.com/download/pdf/xolair_prescribing.pdf . Accessed: October 2025.

16. Nucala (mepolizumab) Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/nucala-epar-product-information_en.pdf . Accessed October 2025.

17. Nucala (mepolizumab) US prescribing information; Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761122s006,125526s018lbl.pdf . Accessed October 2025.

18. Dupixent (dupilumab) Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/dupixent-epar-product-information_en.pdf . Accessed October 2025.

19. Dupixent (dupilumab) US prescribing information; Available at: https://www.regeneron.com/downloads/dupixent_fpi.pdf . Accessed October 2025.

20. Clinicaltrials.gov. Efficacy and Safety